1
|
King C, Einhorn L, Brusselaers N, Carlsson M, Einhorn S, Elgh F, Frisén J, Gustafsson Å, Hanson S, Hanson C, Hedner T, Isaksson O, Jansson A, Lundkvist Å, Lötvall J, Lundback B, Olsen B, Söderberg-Nauclér C, Wahlin A, Steineck G, Vahlne A. COVID-19-a very visible pandemic. Lancet 2020; 396:e15. [PMID: 32771110 PMCID: PMC7836894 DOI: 10.1016/s0140-6736(20)31672-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Accepted: 07/08/2020] [Indexed: 01/17/2023]
Affiliation(s)
- Carina King
- Department of Global Public Health, Karolinska Institutet, Stockholm SE-171 77, Sweden; Institute for Global Health, University College London, London, UK.
| | | | - Nele Brusselaers
- Department of Microbiology Tumour and Cell Biology, Karolinska Institutet, Stockholm SE-171 77, Sweden
| | | | - Stefan Einhorn
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm SE-171 77, Sweden
| | - Fredrik Elgh
- Department of Clinical Microbiology, Umeå University, Umeå, Sweden
| | - Jonas Frisén
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm SE-171 77, Sweden
| | - Åke Gustafsson
- Department of Clinical Microbiology, Umeå University, Umeå, Sweden
| | | | - Claudia Hanson
- Department of Global Public Health, Karolinska Institutet, Stockholm SE-171 77, Sweden
| | - Thomas Hedner
- The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Olle Isaksson
- The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Anders Jansson
- Department of Clinical Physiology, Danderyd Hospital, Stockholm, Sweden
| | - Åke Lundkvist
- Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
| | - Jan Lötvall
- Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Bo Lundback
- Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Björn Olsen
- Zoonosis Science Centre, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
| | - Cecilia Söderberg-Nauclér
- Department of Medicine, Karolinska Institutet, Stockholm SE-171 77, Sweden; Department of Neurology, Karolinska Institutet, Stockholm SE-171 77, Sweden
| | - Anders Wahlin
- Department of Radiation Sciences, Umeå University, Umeå, Sweden
| | - Gunner Steineck
- Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden
| | - Anders Vahlne
- Department of Clinical Microbiology, Karolinska Institutet, Stockholm SE-171 77, Sweden
| |
Collapse
|
2
|
Mellgren K, Friberg L, Hedner T, Mellgren G, Wadenvik H. Blood Platelet Activation and Membrane Glycoprotein Changes during Extracorporeal Life Support (Ecls). In Vitro Studies. Int J Artif Organs 2018. [DOI: 10.1177/039139889501800604] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The aim of this study was to evaluate an in vitro model for investigation of platelet function parameters in an extracorporeal system. Two different perfusion pumps were compared, a roller pump (Polystan) and a centrifugal pump (Biomedicus). A continuous increase in glycoprotein (GP)1b-negative platelets was observed in both circuits. A marked increase of plasma β-thromboglobulin thromboglobulin concentration and a decrease of the intracellular pool of serotonin was observed, indicating a marked release of alpha as well as of dense granules. The plasma concentration of glycocalicin increased in parallel with a reduced platelet surface expression of GP1b, suggesting that the loss of GP1b is caused by proteolysis rather than by a downregulation of this receptor protein. It is concluded that ECLS results in a pronounced platelet degranulation and causes changes of important membrane receptors which might explain some of the bleeding problems observed in patients treated with ECLS. No significant difference was noted between the roller pump and the centrifugal pump. Trial of strategies, e.g. protease inhibitors and nitric oxide to revert this untoward effect of ECLS are highly warranted.
Collapse
Affiliation(s)
- K. Mellgren
- Department of Pediatric Surgery, Östra Hospital, University of Göteborg, Göteborg - Sweden
| | - L.G. Friberg
- Department of Pediatric Surgery, Östra Hospital, University of Göteborg, Göteborg - Sweden
| | - T. Hedner
- Department of Clinical Pharmacology, University of Göteborg, Göteborg - Sweden
| | - G. Mellgren
- Department of Pediatric Surgery, Östra Hospital, University of Göteborg, Göteborg - Sweden
| | - H. Wadenvik
- Department of Medicine, Sahlgrenska Hospital, University of Göteborg, Göteborg - Sweden
| |
Collapse
|
3
|
Kjeldsen SE, Hedner T, Narkiewicz K. HOPE-3, SPRINT, VALUE and a meta-analysis of trials in patients with diabetes support treatment of hypertension to a target below 140 mmHg. Blood Press 2016; 25:131-2. [DOI: 10.1080/08037051.2016.1182857] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Sverre E. Kjeldsen
- Department of Cardiology, University of Oslo, Ullevaal Hospital, Oslo, Norway
| | - Thomas Hedner
- Department of Medicine, University of Göteborg, Sahlgrenska Academy, Göteborg, Sweden
| | - Krzysztof Narkiewicz
- Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland
| |
Collapse
|
4
|
Hedner T, Kjeldsen SE, Narkiewicz K, Oparil S. The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease. Blood Press 2016; 25:276-9. [DOI: 10.3109/08037051.2016.1139324] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
5
|
Holgersson M, Phan T, Hedner T. Entrepreneurial patent management in pharmaceutical startups. Drug Discov Today 2016; 21:1042-5. [PMID: 26948802 DOI: 10.1016/j.drudis.2016.02.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 02/08/2016] [Accepted: 02/25/2016] [Indexed: 10/22/2022]
Abstract
Startups fill an increasingly important role as innovators in the pharmaceutical industry, and patenting is typically central to their success. This article aims to explore patent management in pharmaceutical startups. The results show that startups need to deal with several challenges related to patenting and an 'entrepreneurial' approach to patent management is called for. Resource constraints, venture capital provision, exits and other conditions and events must be readily considered in the patent management process to build a successful pharmaceutical venture, something that could benefit the pharmaceutical industry as a whole.
Collapse
Affiliation(s)
- Marcus Holgersson
- Department of Technology Management and Economics, Chalmers University of Technology, 412 96 Gothenburg, Sweden.
| | - Tai Phan
- Innovation and Entrepreneurship, Sahlgrenska Academy, University of Gothenburg, Box 417, 405 30 Gothenburg, Sweden
| | - Thomas Hedner
- Innovation and Entrepreneurship, Sahlgrenska Academy, University of Gothenburg, Box 417, 405 30 Gothenburg, Sweden
| |
Collapse
|
6
|
Elliott HL, Kjeldsen SE, Narkiewicz K, Hedner T. Peter Meredith. Blood Press 2016; 25:129-30. [DOI: 10.3109/08037051.2016.1139360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
7
|
Kjeldsen SE, Narkiewicz K, Hedner T, Mancia G. The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg. Blood Press 2016; 25:63-6. [DOI: 10.3109/08037051.2015.1130775] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
8
|
Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. Blood Press 2015; 25:1-3. [DOI: 10.3109/08037051.2016.1096564] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
9
|
Kelloniemi A, Szabo Z, Serpi R, Näpänkangas J, Ohukainen P, Tenhunen O, Kaikkonen L, Koivisto E, Bagyura Z, Kerkelä R, Leosdottir M, Hedner T, Melander O, Ruskoaho H, Rysä J. The Early-Onset Myocardial Infarction Associated PHACTR1 Gene Regulates Skeletal and Cardiac Alpha-Actin Gene Expression. PLoS One 2015; 10:e0130502. [PMID: 26098115 PMCID: PMC4476650 DOI: 10.1371/journal.pone.0130502] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Accepted: 05/19/2015] [Indexed: 11/19/2022] Open
Abstract
The phosphatase and actin regulator 1 (PHACTR1) locus is a very commonly identified hit in genome-wide association studies investigating coronary artery disease and myocardial infarction (MI). However, the function of PHACTR1 in the heart is still unknown. We characterized the mechanisms regulating Phactr1 expression in the heart, used adenoviral gene delivery to investigate the effects of Phactr1 on cardiac function, and analyzed the relationship between MI associated PHACTR1 allele and cardiac function in human subjects. Phactr1 mRNA and protein levels were markedly reduced (60%, P<0.01 and 90%, P<0.001, respectively) at 1 day after MI in rats. When the direct myocardial effects of Phactr1 were studied, the skeletal α-actin to cardiac α-actin isoform ratio was significantly higher (1.5-fold, P<0.05) at 3 days but 40% lower (P<0.05) at 2 weeks after adenovirus-mediated Phactr1 gene delivery into the anterior wall of the left ventricle. Similarly, the skeletal α-actin to cardiac α-actin ratio was lower at 2 weeks in infarcted hearts overexpressing Phactr1. In cultured neonatal cardiac myocytes, adenovirus-mediated Phactr1 overexpression for 48 hours markedly increased the skeletal α-actin to cardiac α-actin ratio, this being associated with an enhanced DNA binding activity of serum response factor. Phactr1 overexpression exerted no major effects on the expression of other cardiac genes or LV structure and function in normal and infarcted hearts during 2 weeks’ follow-up period. In human subjects, MI associated PHACTR1 allele was not associated significantly with cardiac function (n = 1550). Phactr1 seems to regulate the skeletal to cardiac α-actin isoform ratio.
Collapse
Affiliation(s)
- Annina Kelloniemi
- Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Zoltan Szabo
- Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Raisa Serpi
- Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Juha Näpänkangas
- Department of Pathology, Oulu University Hospital, University of Oulu, Oulu, Finland
| | - Pauli Ohukainen
- Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Olli Tenhunen
- Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Leena Kaikkonen
- Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Elina Koivisto
- Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Zsolt Bagyura
- Heart Center, Semmelweis University, Budapest, Hungary
| | - Risto Kerkelä
- Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
- Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland
| | | | - Thomas Hedner
- Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Olle Melander
- Lund University, Department of Clinical Sciences, Malmö, Sweden
| | - Heikki Ruskoaho
- Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
- * E-mail: (JR); (HR)
| | - Jaana Rysä
- Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
- * E-mail: (JR); (HR)
| |
Collapse
|
10
|
Moilanen AM, Rysä J, Kaikkonen L, Karvonen T, Mustonen E, Serpi R, Szabó Z, Tenhunen O, Bagyura Z, Näpänkangas J, Ohukainen P, Tavi P, Kerkelä R, Leósdóttir M, Wahlstrand B, Hedner T, Melander O, Ruskoaho H. WDR12, a Member of Nucleolar PeBoW-Complex, Is Up-Regulated in Failing Hearts and Causes Deterioration of Cardiac Function. PLoS One 2015; 10:e0124907. [PMID: 25915632 PMCID: PMC4411154 DOI: 10.1371/journal.pone.0124907] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2014] [Accepted: 03/09/2015] [Indexed: 01/13/2023] Open
Abstract
Aims In a recent genome-wide association study, WD-repeat domain 12 (WDR12) was associated with early-onset myocardial infarction (MI). However, the function of WDR12 in the heart is unknown. Methods and Results We characterized cardiac expression of WDR12, used adenovirus-mediated WDR12 gene delivery to examine effects of WDR12 on left ventricular (LV) remodeling, and analyzed relationship between MI associated WDR12 allele and cardiac function in human subjects. LV WDR12 protein levels were increased in patients with dilated cardiomyopathy and rats post-infarction. In normal adult rat hearts, WDR12 gene delivery into the anterior wall of the LV decreased interventricular septum diastolic and systolic thickness and increased the diastolic and systolic diameters of the LV. Moreover, LV ejection fraction (9.1%, P<0.05) and fractional shortening (12.2%, P<0.05) were declined. The adverse effects of WDR12 gene delivery on cardiac function were associated with decreased cellular proliferation, activation of p38 mitogen–activated protein kinase (MAPK)/heat shock protein (HSP) 27 pathway, and increased protein levels of Block of proliferation 1 (BOP1), essential for ribosome biogenesis. Post-infarction WDR12 gene delivery decreased E/A ratio (32%, P<0.05) suggesting worsening of diastolic function. In human subjects, MI associated WDR12 allele was associated significantly with diastolic dysfunction and left atrial size. Conclusions WDR12 triggers distinct deterioration of cardiac function in adult rat heart and the MI associated WDR12 variant is associated with diastolic dysfunction in human subjects.
Collapse
Affiliation(s)
- Anne-Mari Moilanen
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
- Department of Pathology, The Institute of Diagnostics, University of Oulu, Oulu, Finland
- Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
| | - Jaana Rysä
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Leena Kaikkonen
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Teemu Karvonen
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Erja Mustonen
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Raisa Serpi
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
- Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland
| | - Zoltán Szabó
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Olli Tenhunen
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Zsolt Bagyura
- Heart Center, Semmelweis University, Budapest, Hungary
| | - Juha Näpänkangas
- Department of Pathology, The Institute of Diagnostics, University of Oulu, Oulu, Finland
| | - Pauli Ohukainen
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Pasi Tavi
- Department of Biotechnology and Molecular Medicine, A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Risto Kerkelä
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
- Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
| | - Margrét Leósdóttir
- Department of Clinical Sciences, Lund University, Lund, Sweden
- Department of Cardiology, Skåne University Hospital, Malmö, Sweden
| | - Björn Wahlstrand
- Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Thomas Hedner
- Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Olle Melander
- Department of Clinical Sciences, Lund University, Lund, Sweden
- Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden
| | - Heikki Ruskoaho
- The Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
- Division of Pharmacology and Pharmacotherapy, University of Helsinki, Helsinki, Finland
- * E-mail:
| |
Collapse
|
11
|
Kjeldsen SE, Narkiewicz K, Oparil S, Hedner T. Renal denervation in treatment-resistant hypertension – Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials. Blood Press 2014; 23:135-7. [DOI: 10.3109/08037051.2014.916896] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Sverre E. Kjeldsen
- Department of Cardiology, University of Oslo, Ullevaal Hospital,
Oslo, Norway
| | - Krzysztof Narkiewicz
- Department of Hypertension and Diabetology, Medical University of Gdansk, Poland
| | - Suzanne Oparil
- Vascular Biology and Hypertension Program, University of Alabama,
Birmingham, Alabama, USA
| | - Thomas Hedner
- Department of Medicine, University of Göteborg, Sahlgrenska Academy,
Göteborg, Sweden
| |
Collapse
|
12
|
Svensson PA, Wahlstrand B, Olsson M, Froguel P, Falchi M, Bergman RN, McTernan PG, Hedner T, Carlsson LMS, Jacobson P. CDKN2B expression and subcutaneous adipose tissue expandability: possible influence of the 9p21 atherosclerosis locus. Biochem Biophys Res Commun 2014; 446:1126-31. [PMID: 24680834 PMCID: PMC4003348 DOI: 10.1016/j.bbrc.2014.03.075] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2014] [Accepted: 03/17/2014] [Indexed: 11/22/2022]
Abstract
The tumor suppressor gene CDKN2B is highly expressed in human adipose tissue. Risk alleles at the 9p21 locus modify CDKN2B expression in a BMI-dependent fashion. There is an inverse relationship between expression of CDKN2B and adipogenic genes. CDKN2B expression influences to postprandial triacylglycerol clearance. CDKN2B expression in adipose tissue is linked to markers of hepatic steatosis.
Risk alleles within a gene desert at the 9p21 locus constitute the most prevalent genetic determinant of cardiovascular disease. Previous research has demonstrated that 9p21 risk variants influence gene expression in vascular tissues, yet the biological mechanisms by which this would mediate atherosclerosis merits further investigation. To investigate possible influences of this locus on other tissues, we explored expression patterns of 9p21-regulated genes in a panel of multiple human tissues and found that the tumor suppressor CDKN2B was highly expressed in subcutaneous adipose tissue (SAT). CDKN2B expression was regulated by obesity status, and this effect was stronger in carriers of 9p21 risk alleles. Covariation between expression of CDKN2B and genes implemented in adipogenesis was consistent with an inhibitory effect of CDKN2B on SAT proliferation. Moreover, studies of postprandial triacylglycerol clearance indicated that CDKN2B is involved in down-regulation of SAT fatty acid trafficking. CDKN2B expression in SAT correlated with indicators of ectopic fat accumulation, including markers of hepatic steatosis. Among genes regulated by 9p21 risk variants, CDKN2B appears to play a significant role in the regulation of SAT expandability, which is a strong determinant of lipotoxicity and therefore might contribute to the development of atherosclerosis.
Collapse
Affiliation(s)
- Per-Arne Svensson
- Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Sweden
| | - Björn Wahlstrand
- Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Sweden
| | - Maja Olsson
- Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Sweden
| | - Philippe Froguel
- Department of Genomics of Common Disease, School of Public Health, Imperial College London, UK
| | - Mario Falchi
- Department of Genomics of Common Disease, School of Public Health, Imperial College London, UK
| | - Richard N Bergman
- Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Philip G McTernan
- Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK
| | - Thomas Hedner
- Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Sweden
| | - Lena M S Carlsson
- Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Sweden
| | - Peter Jacobson
- Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Sweden.
| |
Collapse
|
13
|
Affiliation(s)
- Sverre E. Kjeldsen
- Department of Cardiology, University of Oslo, Ullevaal Hospital,
Oslo, Norway
| | - Krzystof Narkiewicz
- Department of Hypertension and Diabetology, Medical University of Gdansk, Poland
| | - Suzanne Oparil
- Vascular Biology and Hypertension Program, University of Alabama at Birmingham, USA
| | - Thomas Hedner
- Department of Medicine, University of Göteborg, Sahlgrenska Academy,
Göteborg, Sweden
| |
Collapse
|
14
|
Kjeldsen SE, Narkiewicz K, Oparil S, Hedner T. Blood pressure lowering effect of renal sympathetic denervation or placebo? - building expectations for Symplicity-HTN 3. Blood Press 2013; 22:279-81. [DOI: 10.3109/08037051.2013.840445] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
15
|
Hedner T, Kjeldsen SE, Narkiewicz K. Combination treatment in hypertension - the latest 2013 European Guidelines. Blood Press 2013; 22 Suppl 1:1-2. [PMID: 23978052 DOI: 10.3109/08037051.2013.826471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
16
|
|
17
|
Fernandez C, Sandin M, Sampaio JL, Almgren P, Narkiewicz K, Hoffmann M, Hedner T, Wahlstrand B, Simons K, Shevchenko A, James P, Melander O. Plasma lipid composition and risk of developing cardiovascular disease. PLoS One 2013; 8:e71846. [PMID: 23967253 PMCID: PMC3744469 DOI: 10.1371/journal.pone.0071846] [Citation(s) in RCA: 100] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Accepted: 07/04/2013] [Indexed: 12/14/2022] Open
Abstract
Aims We tested whether characteristic changes of the plasma lipidome in individuals with comparable total lipids level associate with future cardiovascular disease (CVD) outcome and whether 23 validated gene variants associated with coronary artery disease (CAD) affect CVD associated lipid species. Methods and Results Screening of the fasted plasma lipidome was performed by top-down shotgun analysis and lipidome compositions compared between incident CVD cases (n = 211) and controls (n = 216) from the prospective population-based MDC study using logistic regression adjusting for Framingham risk factors. Associations with incident CVD were seen for eight lipid species (0.21≤q≤0.23). Each standard deviation unit higher baseline levels of two lysophosphatidylcholine species (LPC), LPC16∶0 and LPC20∶4, was associated with a decreased risk for CVD (P = 0.024–0.028). Sphingomyelin (SM) 38∶2 was associated with increased odds of CVD (P = 0.057). Five triglyceride (TAG) species were associated with protection (P = 0.031–0.049). LPC16∶0 was negatively correlated with the carotid intima-media thickness (P = 0.010) and with HbA1c (P = 0.012) whereas SM38∶2 was positively correlated with LDL-cholesterol (P = 0.0*10−6) and the q-values were good (q≤0.03). The risk allele of 8 CAD-associated gene variants showed significant association with the plasma level of several lipid species. However, the q-values were high for many of the associations (0.015≤q≤0.75). Risk allele carriers of 3 CAD-loci had reduced level of LPC16∶0 and/or LPC 20∶4 (P≤0.056). Conclusion Our study suggests that CVD development is preceded by reduced levels of LPC16∶0, LPC20∶4 and some specific TAG species and by increased levels of SM38∶2. It also indicates that certain lipid species are intermediate phenotypes between genetic susceptibility and overt CVD. But it is a preliminary study that awaits replication in a larger population because statistical significance was lost for the associations between lipid species and future cardiovascular events when correcting for multiple testing.
Collapse
Affiliation(s)
- Celine Fernandez
- Department of Clinical Sciences, Lund University, Malmö, Sweden
- * E-mail: (CF); (OM)
| | - Marianne Sandin
- Department of Immunotechnology, Lund University, Lund, Sweden
| | - Julio L. Sampaio
- Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
| | - Peter Almgren
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Krzysztof Narkiewicz
- Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland
| | - Michal Hoffmann
- Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland
| | - Thomas Hedner
- Department of Medicine, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
| | - Björn Wahlstrand
- Department of Medicine, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
| | - Kai Simons
- Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
| | - Andrej Shevchenko
- Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
| | - Peter James
- Department of Immunotechnology, Lund University, Lund, Sweden
| | - Olle Melander
- Department of Clinical Sciences, Lund University, Malmö, Sweden
- * E-mail: (CF); (OM)
| |
Collapse
|
18
|
Kjeldsen SE, Narkiewicz K, Oparil S, Hedner T. 2013 European Society of Hypertension/European Society of Cardiology Hypertension Guidelines. Blood Press 2013; 22:191-2. [DOI: 10.3109/08037051.2013.817814] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
19
|
Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, McDonough CW, Beitelshees AL, Schwartz GL, Gums JG, Padmanabhan S, Hiltunen TP, Citterio L, Donner KM, Hedner T, Lanzani C, Melander O, Saarela J, Ripatti S, Wahlstrand B, Manunta P, Kontula K, Dominiczak AF, Cooper-DeHoff RM, Johnson JA. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension 2013; 62:391-7. [PMID: 23753411 DOI: 10.1161/hypertensionaha.111.00436] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
To identify novel genes influencing blood pressure response to thiazide diuretic therapy for hypertension, we conducted genome-wide association meta-analyses of ≈1.1 million single-nucleotide polymorphisms in a combined sample of 424 European Americans with primary hypertension treated with hydrochlorothiazide from the Pharmacogenomic Evaluation of Antihypertensive Responses study (n=228) and the Genetic Epidemiology of Responses to Antihypertensive study (n=196). Polymorphisms associated with blood pressure response at P<10(-5) were tested for replication of the associations in independent samples of hydrochlorothiazide-treated European hypertensives. The rs16960228 polymorphism in protein kinase C, α replicated for same-direction association with diastolic blood pressure response in the Nordic Diltiazem study (n=420) and the Genetics of Drug Responsiveness in Essential Hypertension study (n=206), and the combined 4-study meta-analysis P value achieved genome-wide significance (P=3.3 × 10(-8)). Systolic or diastolic blood pressure responses were consistently greater in carriers of the rs16960228 A allele than in GG homozygotes (>4/4 mm Hg) across study samples. The rs2273359 polymorphism in the GNAS-EDN3 region also replicated for same-direction association with systolic blood pressure response in the Nordic Diltiazem study, and the combined 3-study meta-analysis P value approached genome-wide significance (P=5.5 × 10(-8)). The findings document clinically important effects of genetic variation at novel loci on blood pressure response to a thiazide diuretic, which may be a basis for individualization of antihypertensive drug therapy and identification of new drug targets.
Collapse
Affiliation(s)
- Stephen T Turner
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Hedner T, Narkiewicz K, Oparil S, Kjeldsen SE. Primary cardiovascular prevention by Mediterranean diet - the PREDIMED trial. Blood Press 2013; 22:129-30. [PMID: 23659248 DOI: 10.3109/08037051.2013.793882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
21
|
Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S. Revisiting the pre-hypertension debate: increasing evidence for treatment--or not? Blood Press 2013; 22:344. [PMID: 23635037 DOI: 10.3109/08037051.2013.787711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Sverre E Kjeldsen
- Department of Cardiology, University of Oslo, Ullevaal Hospital , Oslo , Norway
| | | | | | | |
Collapse
|
22
|
Larsson E, Wahlstrand B, Hedblad B, Hedner T, Kjeldsen SE, Melander O, Lindahl P. Hypertension and genetic variation in endothelial-specific genes. PLoS One 2013; 8:e62035. [PMID: 23637959 PMCID: PMC3639261 DOI: 10.1371/journal.pone.0062035] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2012] [Accepted: 03/18/2013] [Indexed: 01/11/2023] Open
Abstract
Genome-wide association (GWA) studies usually detect common genetic variants with low-to-medium effect sizes. Many contributing variants are not revealed, since they fail to reach significance after strong correction for multiple comparisons. The WTCCC study for hypertension, for example, failed to identify genome-wide significant associations. We hypothesized that genetic variation in genes expressed specifically in the endothelium may be important for hypertension development. Results from the WTCCC study were combined with previously published gene expression data from mice to specifically investigate SNPs located within endothelial-specific genes, bypassing the requirement for genome-wide significance. Six SNPs from the WTCCC study were selected for independent replication in 5205 hypertensive patients and 5320 population-based controls, and successively in a cohort of 16537 individuals. A common variant (rs10860812) in the DRAM (damage-regulated autophagy modulator) locus showed association with hypertension (P = 0.008) in the replication study. The minor allele (A) had a protective effect (OR = 0.93; 95% CI 0.88–0.98 per A-allele), which replicates the association in the WTCCC GWA study. However, a second follow-up, in the larger cohort, failed to reveal an association with blood pressure. We further tested the endothelial-specific genes for co-localization with a panel of newly discovered SNPs from large meta-GWAS on hypertension or blood pressure. There was no significant overlap between those genes and hypertension or blood pressure loci. The result does not support the hypothesis that genetic variation in genes expressed in endothelium plays an important role for hypertension development. Moreover, the discordant association of rs10860812 with blood pressure in the case control study versus the larger Malmö Preventive Project–study highlights the importance of rigorous replication in multiple large independent studies.
Collapse
Affiliation(s)
- Erik Larsson
- Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
- * E-mail: (EL); (PL)
| | - Björn Wahlstrand
- Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - Bo Hedblad
- Clinical research Center (CRC), Malmö University Hospital, Malmö, Sweden
| | - Thomas Hedner
- Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - Sverre E. Kjeldsen
- Department of Cardiology/Cardiovascular and Renal Research Center, Ullevaal University Hospital, Oslo, Norway
| | - Olle Melander
- Clinical research Center (CRC), Malmö University Hospital, Malmö, Sweden
| | - Per Lindahl
- Wallenberg Laboratory, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
- * E-mail: (EL); (PL)
| |
Collapse
|
23
|
Edgar B, Abouzeedan A, Hedner T, Maack K, Lundqvist M. Using scenario planning in regional development context: the challenges and opportunities. ACTA ACUST UNITED AC 2013. [DOI: 10.1108/20425941311323118] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
24
|
Hedner T, Larkö O. [Swedish research needs Swedish innovation. The research and innovation strategy must strengthen Swedish competitiveness]. Lakartidningen 2013; 110:204-205. [PMID: 23451670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
|
25
|
Alvarez-Madrazo S, MacKenzie SM, Davies E, Fraser R, Lee WK, Brown M, Caulfield MJ, Dominiczak AF, Farrall M, Lathrop M, Hedner T, Melander O, Munroe PB, Samani N, Stewart PM, Wahlstrand B, Webster J, Palmer CN, Padmanabhan S, Connell JM. Common Polymorphisms in the
CYP11B1
and
CYP11B2
Genes: Evidence for a Digenic Influence on Hypertension. Hypertension 2013; 61:232-9. [DOI: 10.1161/hypertensionaha.112.200741] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Samantha Alvarez-Madrazo
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Scott M. MacKenzie
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Eleanor Davies
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Robert Fraser
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Wai-Kwong Lee
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Morris Brown
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Mark J. Caulfield
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Anna F. Dominiczak
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Martin Farrall
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Mark Lathrop
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Thomas Hedner
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Olle Melander
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Patricia B. Munroe
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Nilesh Samani
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Paul M. Stewart
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Björn Wahlstrand
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - John Webster
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Colin N.A. Palmer
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - Sandosh Padmanabhan
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| | - John M. Connell
- From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.A-M., S.M.M., E.D., R.F., W-K.L., A.F.D., S.P.); Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom (M.B.); Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical and Dental School, Queen Mary University of London, London, United Kingdom (M.J.C., P.B.M.)
| |
Collapse
|
26
|
Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S. Angiotensin receptor - neprilysin inhibiton (ARNI) – A novel therapeutic concept for management of hypertension and heart failure. Blood Press 2012; 21:329-30. [DOI: 10.3109/10582452.2012.741765] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
27
|
Hedner T, Narkiewicz K, Oparil S, Kjeldsen SE. Direct renin inhibitors in hypertension - approaching the moment of truth. Blood Press 2012; 21:267-8. [PMID: 23013445 DOI: 10.3109/08037051.2012.728304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
28
|
Hedner T, Kjeldsen SE, Julius S, Zanchetti A. Obituary – Björn Folkow. Blood Press 2012. [DOI: 10.3109/08037051.2012.728046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
29
|
Hedner T, Gatenbeck L. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness]. Lakartidningen 2012; 109:1280-1281. [PMID: 22852257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
|
30
|
Hedner T, Thornblad T, Edgar B, Cowlrick I, Olausson M, Lind L, Klofsten M. [Major changes in the global pharmaceutical industry]. Lakartidningen 2012; 109:324-325. [PMID: 22574425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
31
|
Abouzeedan A, Klofsten M, Hedner T. Implementing the SIV model on an intensively innovation‐oriented firm: the case of Autoadapt AB. W Jnl of Ent Man and Sust Dev 2012. [DOI: 10.1108/20425961211247743] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
32
|
Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S. Increased time varying heart rate and cardiovascular risk in hypertension – Benefit of selective I (f)channel inhibitor? Blood Press 2012; 21:1-2. [DOI: 10.3109/08037051.2012.652818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
33
|
|
34
|
Johnson T, Gaunt T, Newhouse S, Padmanabhan S, Tomaszewski M, Kumari M, Morris R, Tzoulaki I, O'Brien E, Poulter N, Sever P, Shields D, Thom S, Wannamethee S, Whincup P, Brown M, Connell J, Dobson R, Howard P, Mein C, Onipinla A, Shaw-Hawkins S, Zhang Y, Smith G, Day I, Lawlor D, Goodall A, Fowkes F, Abecasis G, Elliott P, Gateva V, Braund P, Burton P, Nelson C, Tobin M, van der Harst P, Glorioso N, Neuvrith H, Salvi E, Staessen J, Stucchi A, Devos N, Jeunemaitre X, Plouin PF, Tichet J, Juhanson P, Org E, Putku M, Sõber S, Veldre G, Viigimaa M, Levinsson A, Rosengren A, Thelle D, Hastie C, Hedner T, Lee W, Melander O, Wahlstrand B, Hardy R, Wong A, Cooper J, Palmen J, Chen L, Stewart A, Wells G, Westra HJ, Wolfs M, Clarke R, Franzosi M, Goel A, Hamsten A, Lathrop M, Peden J, Seedorf U, Watkins H, Ouwehand W, Sambrook J, Stephens J, Casas JP, Drenos F, Holmes M, Kivimaki M, Shah S, Shah T, Talmud P, Whittaker J, Wallace C, Delles C, Laan M, Kuh D, Humphries S, Nyberg F, Cusi D, Roberts R, Newton-Cheh C, Franke L, Stanton A, Dominiczak A, Farrall M, Hingorani A, Samani N, Caulfield M, Munroe P, Caulfield MJ, Munroe PB. Blood pressure loci identified with a gene-centric array. Am J Hum Genet 2011; 89:688-700. [PMID: 22100073 DOI: 10.1016/j.ajhg.2011.10.013] [Citation(s) in RCA: 132] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2011] [Revised: 09/21/2011] [Accepted: 10/27/2011] [Indexed: 12/15/2022] Open
Abstract
Raised blood pressure (BP) is a major risk factor for cardiovascular disease. Previous studies have identified 47 distinct genetic variants robustly associated with BP, but collectively these explain only a few percent of the heritability for BP phenotypes. To find additional BP loci, we used a bespoke gene-centric array to genotype an independent discovery sample of 25,118 individuals that combined hypertensive case-control and general population samples. We followed up four SNPs associated with BP at our p < 8.56 × 10(-7) study-specific significance threshold and six suggestively associated SNPs in a further 59,349 individuals. We identified and replicated a SNP at LSP1/TNNT3, a SNP at MTHFR-NPPB independent (r(2) = 0.33) of previous reports, and replicated SNPs at AGT and ATP2B1 reported previously. An analysis of combined discovery and follow-up data identified SNPs significantly associated with BP at p < 8.56 × 10(-7) at four further loci (NPR3, HFE, NOS3, and SOX6). The high number of discoveries made with modest genotyping effort can be attributed to using a large-scale yet targeted genotyping array and to the development of a weighting scheme that maximized power when meta-analyzing results from samples ascertained with extreme phenotypes, in combination with results from nonascertained or population samples. Chromatin immunoprecipitation and transcript expression data highlight potential gene regulatory mechanisms at the MTHFR and NOS3 loci. These results provide candidates for further study to help dissect mechanisms affecting BP and highlight the utility of studying SNPs and samples that are independent of those studied previously even when the sample size is smaller than that in previous studies.
Collapse
|
35
|
|
36
|
Hedner T, Narkiewicz K, Oparil S, Kjeldsen S. An appropriate SCORE to assess cardiovascular risk in hypertension? Blood Press 2011; 20:320-1. [DOI: 10.3109/08037051.2011.625628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
37
|
|
38
|
Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. High mortality explained by mildly elevated blood pressure in Scandinavian adolescent conscripts: a plea for early drug treatment? Blood Press 2011; 20:188-9. [PMID: 21780952 DOI: 10.3109/08037051.2011.595962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
39
|
|
40
|
Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S. Treatment of high blood pressure in acute stroke--the SCAST study. Blood Press 2011; 20:67-8. [PMID: 21405956 DOI: 10.3109/08037051.2011.564914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
41
|
|
42
|
Hedner T, Oparil S, Narkiewicz K, Os I. Cardiovascular risks in HIV patients. Blood Press 2010; 19:325-7. [PMID: 21080761 DOI: 10.3109/08037051.2010.537016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
43
|
Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D, Hastie CE, Menni C, Monti MC, Delles C, Laing S, Corso B, Navis G, Kwakernaak AJ, van der Harst P, Bochud M, Maillard M, Burnier M, Hedner T, Kjeldsen S, Wahlstrand B, Sjögren M, Fava C, Montagnana M, Danese E, Torffvit O, Hedblad B, Snieder H, Connell JMC, Brown M, Samani NJ, Farrall M, Cesana G, Mancia G, Signorini S, Grassi G, Eyheramendy S, Wichmann HE, Laan M, Strachan DP, Sever P, Shields DC, Stanton A, Vollenweider P, Teumer A, Völzke H, Rettig R, Newton-Cheh C, Arora P, Zhang F, Soranzo N, Spector TD, Lucas G, Kathiresan S, Siscovick DS, Luan J, Loos RJF, Wareham NJ, Penninx BW, Nolte IM, McBride M, Miller WH, Nicklin SA, Baker AH, Graham D, McDonald RA, Pell JP, Sattar N, Welsh P, Munroe P, Caulfield MJ, Zanchetti A, Dominiczak AF. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet 2010; 6:e1001177. [PMID: 21082022 PMCID: PMC2965757 DOI: 10.1371/journal.pgen.1001177] [Citation(s) in RCA: 258] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2010] [Accepted: 09/23/2010] [Indexed: 12/19/2022] Open
Abstract
Hypertension is a heritable and major contributor to the global burden of disease. The sum of rare and common genetic variants robustly identified so far explain only 1%–2% of the population variation in BP and hypertension. This suggests the existence of more undiscovered common variants. We conducted a genome-wide association study in 1,621 hypertensive cases and 1,699 controls and follow-up validation analyses in 19,845 cases and 16,541 controls using an extreme case-control design. We identified a locus on chromosome 16 in the 5′ region of Uromodulin (UMOD; rs13333226, combined P value of 3.6×10−11). The minor G allele is associated with a lower risk of hypertension (OR [95%CI]: 0.87 [0.84–0.91]), reduced urinary uromodulin excretion, better renal function; and each copy of the G allele is associated with a 7.7% reduction in risk of CVD events after adjusting for age, sex, BMI, and smoking status (H.R. = 0.923, 95% CI 0.860–0.991; p = 0.027). In a subset of 13,446 individuals with estimated glomerular filtration rate (eGFR) measurements, we show that rs13333226 is independently associated with hypertension (unadjusted for eGFR: 0.89 [0.83–0.96], p = 0.004; after eGFR adjustment: 0.89 [0.83–0.96], p = 0.003). In clinical functional studies, we also consistently show the minor G allele is associated with lower urinary uromodulin excretion. The exclusive expression of uromodulin in the thick portion of the ascending limb of Henle suggests a putative role of this variant in hypertension through an effect on sodium homeostasis. The newly discovered UMOD locus for hypertension has the potential to give new insights into the role of uromodulin in BP regulation and to identify novel drugable targets for reducing cardiovascular risk. Hypertension is the leading contributor to global mortality with a global prevalence of 26.4% in 2000, projected to increase to 29.2% by 2025. While 50%–60% of population variation in blood pressure can be attributable to additive genetic factors, all the genetic variants robustly identified so far explain only 1%–2% of the population variance indicating the presence of additional undiscovered risk variants. Using an extreme case-control strategy, we have discovered a SNP in the promoter region of the uromodulin gene (UMOD) to be associated with hypertension (minor allele protective against hypertension). We then validated this association using large-scale population and case-control studies, where similar extreme criteria for selection of cases and controls have been used (21,466 cases and 18,240 controls). As the locus was related to uromodulin, a protein exclusively expressed in the kidneys, we show that the association is independent of renal dysfunction. We also show preliminary evidence that the SNP allele which is protective against hypertension is also protective against cardiovascular events in 26,654 Swedish subjects followed-up for 12 years. The newly discovered UMOD locus for hypertension has the potential to give unique insights into the role of uromodulin in BP regulation and to identify novel drugable targets.
Collapse
Affiliation(s)
- Sandosh Padmanabhan
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Olle Melander
- Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, University Hospital Malmö, Lund University, Malmö, Sweden
| | - Toby Johnson
- Clinical Pharmacology and Barts and the London Genome Centre, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom
| | | | - Wai K. Lee
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | | | - Claire E. Hastie
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Cristina Menni
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- Università Milano-Bicocca, Dipartimento di Medicina Clinica e Prevenzione, Ospedale San Gerardo, Monza, Milano, Italy
| | - Maria Cristina Monti
- Istituto Auxologico Italiano, Milan, Italy
- Department of Health Science, University of Pavia, Pavia, Italy
| | - Christian Delles
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Stewart Laing
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Barbara Corso
- Istituto Auxologico Italiano, Milan, Italy
- Department of Health Science, University of Pavia, Pavia, Italy
| | - Gerjan Navis
- Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Arjan J. Kwakernaak
- Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Pim van der Harst
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Murielle Bochud
- University Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Marc Maillard
- Service of Nephrology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Michel Burnier
- Service of Nephrology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Thomas Hedner
- Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Sverre Kjeldsen
- Department of Cardiology, University of Oslo, Ullevaal Hospital, Oslo, Norway
| | - Björn Wahlstrand
- Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Marketa Sjögren
- Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, University Hospital Malmö, Lund University, Malmö, Sweden
| | - Cristiano Fava
- Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, University Hospital Malmö, Lund University, Malmö, Sweden
- Department of Medicine, Section of Internal Medicine C, University of Verona, Verona, Italy
| | - Martina Montagnana
- Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, University Hospital Malmö, Lund University, Malmö, Sweden
- Department of Life and Reproduction Sciences, Section of Clinical Chemistry, University of Verona, Verona, Italy
| | - Elisa Danese
- Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, University Hospital Malmö, Lund University, Malmö, Sweden
- Department of Life and Reproduction Sciences, Section of Clinical Chemistry, University of Verona, Verona, Italy
| | - Ole Torffvit
- Department of Nephrology, Institution of Clinical Sciences, University Hospital of Lund, Lund, Sweden
| | - Bo Hedblad
- Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, University Hospital Malmö, Lund University, Malmö, Sweden
| | - Harold Snieder
- Unit of Genetic Epidemiology and Bioinformatics, Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - John M. C. Connell
- College of Medicine, Dentistry and Nursing, Ninewells Hospital, University of Dundee, Dundee, United Kingdom
| | - Morris Brown
- Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom
| | - Nilesh J. Samani
- Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, United Kingdom
| | - Martin Farrall
- Department of Cardiovascular Medicine, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
| | - Giancarlo Cesana
- Università Milano-Bicocca, Dipartimento di Medicina Clinica e Prevenzione, Ospedale San Gerardo, Monza, Milano, Italy
| | - Giuseppe Mancia
- Università Milano-Bicocca, Dipartimento di Medicina Clinica e Prevenzione, Ospedale San Gerardo, Monza, Milano, Italy
| | | | - Guido Grassi
- Università Milano-Bicocca, Dipartimento di Medicina Clinica e Prevenzione, Ospedale San Gerardo, Monza, Milano, Italy
| | - Susana Eyheramendy
- Department of Statistics, Pontificia Universidad Catolica de Chile, Santiago, Chile
| | - H. Erich Wichmann
- Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
- Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany
| | - Maris Laan
- Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
| | - David P. Strachan
- Division of Community Health Sciences, St George's, University of London, London, United Kingdom
| | - Peter Sever
- International Centre for Circulatory Health National Heart and Lung Institute, Imperial College, London, United Kingdom
| | - Denis Colm Shields
- Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
| | - Alice Stanton
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Peter Vollenweider
- Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Alexander Teumer
- Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany
| | - Henry Völzke
- Institute for Community Medicine, University of Greifswald, Greifswald, Germany
| | - Rainer Rettig
- Institute of Physiology, University of Greifswald, Greifswald, Germany
| | - Christopher Newton-Cheh
- Center for Human Genetic Research and Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Pankaj Arora
- Center for Human Genetic Research and Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Feng Zhang
- Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom
| | - Nicole Soranzo
- Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom
- Wellcome Trust Sanger Institute, Genome Campus, Hinxton, United Kingdom
| | - Timothy D. Spector
- Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom
| | - Gavin Lucas
- Cardiovascular Epidemiology and Genetics Group, Institut Municipal d'Investigacio Medica, Barcelona, Spain
| | - Sekar Kathiresan
- Center for Human Genetic Research and Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
| | - David S. Siscovick
- Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington, United States of America
| | - Jian'an Luan
- MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge, United Kingdom
| | - Ruth J. F. Loos
- MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge, United Kingdom
| | - Nicholas J. Wareham
- MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge, United Kingdom
| | - Brenda W. Penninx
- Department of Psychiatry/EMGO Institute, Neuroscience Campus, VU University Medical Center, Amsterdam, The Netherlands
- Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands
- Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Ilja M. Nolte
- Unit of Genetic Epidemiology and Bioinformatics, Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Martin McBride
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - William H. Miller
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Stuart A. Nicklin
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Andrew H. Baker
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Delyth Graham
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Robert A. McDonald
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Jill P. Pell
- Public Health and Health Policy Section, University of Glasgow, Glasgo, United Kingdom
| | - Naveed Sattar
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Paul Welsh
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | | | - Patricia Munroe
- Clinical Pharmacology and Barts and the London Genome Centre, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom
| | - Mark J. Caulfield
- Clinical Pharmacology and Barts and the London Genome Centre, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom
| | - Alberto Zanchetti
- Istituto Auxologico Italiano, Milan, Italy
- University of Milano, Milano, Italy
| | - Anna F. Dominiczak
- Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- * E-mail:
| |
Collapse
|
44
|
Kjeldsen SE, Hedner T, Oparil S, Narkiewicz K. Angiotensin receptor blockers and cancer - Relationship dismissed by VALUE data while waiting for EMA and FDA reports. Blood Press 2010; 19:271-2. [PMID: 20858047 DOI: 10.3109/08037051.2010.518666] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
45
|
|
46
|
Oparil S, Kjeldsen SE, Narkiewicz K, Hedner T. Blood pressure variability: Emerging role in risk assessment and therapeutics. Blood Press 2010; 19:209-11. [DOI: 10.3109/08037051.2010.510279] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
47
|
|
48
|
Hedner T, Kjeldsen S, Narkiewicz K. Implementation of 24-hour Blood Pressure Control. Blood Press 2010; 1:3-4. [DOI: 10.3109/08037051003668884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
49
|
Hedner T, Kjeldsen S, Narkiewicz K, Oparil S. Hypertension research into the new millennium. Blood Press 2010; 19:1-2. [DOI: 10.3109/08037051003650874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
50
|
Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S. Blood Pressure celebrates 20 years of dedication to Nordic hypertension research. Blood Press 2010; 19:130-1. [DOI: 10.3109/08037051.2010.487989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|